Skip to content
Caroline Dougherty
Caroline Dougherty

Caroline serves as vice president of Corporate Development at Latigo, where she leads business development, corporate strategy, and new product planning. Caroline brings over a decade of experience to her role, including commercial planning across five therapeutic areas and transactions totaling $15 billion across M&A and strategic capital formation.

Prior to Latigo, Caroline held roles of increasing responsibility at Cerevel Therapeutics, most recently leading business development through the company’s $8.7 billion acquisition by Abbvie. Caroline joined Cerevel as one of the first 20 employees and drove multiple mission-critical strategic planning and capital formation projects, including a $125M project financing for Cerevel’s Phase 3 Parkinson’s program. Earlier in her career, Caroline worked in corporate development at Sangamo Therapeutics and in investment banking at Citigroup.

Caroline holds an MBA from Harvard Business School and a BA in Neuroscience and Economics, Magna Cum Laude from Wellesley College.

Back to Team
Back To Top